本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 证券代码：430300 证券简称：辰光医疗 公告编号：2023-093 上海辰光医疗科技股份有限公司 关于公司全资子公司上海辰瞻医疗科技有限公司完成工商 登记并取得营业执照的公告 目前，公司全资子公司上海辰瞻医疗科技有限公司已经完成工商 变更登记手续，并取得上海市青浦区市场监督管理局颁发的营业执照。 登记情况如下： 一、 基本情况 上海辰光医疗科技股份有限公司（以下简称"辰光医疗"）于 2023 年 8 月 5 日召开第五届董事会第二次会议审议通过了《关于公司购买 控股子公司上海辰瞻医疗科技有限公司少数股东股权的议案》。具体 内容详见公司在北京证券交易所官网（www.bse.cn）上披露的《关于 公司购买控股子公司上海辰瞻医疗科技有限公司少数股东股权的公 告》（公告编号：2023-085）。 上海辰光医疗科技股份有限公司的控股子公司上海辰瞻医疗科 技有限公司（以下简称"辰瞻医疗"），注册资本 500 万元，其中辰 光医疗持有 70%的股权出资额为 350 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2023-088 上海辰光医疗科技股份有限公司 第五届监事会第二次会议决议公告 本公司及监事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 （一）审议通过《2023 年半年度报告》 本次会议召开与表决程序符合《中华人民共和国公司法》及《上 海辰光医疗科技股份有限公司公司章程》的规定，所做决议合法有效。 （二）会议出席情况 二、议案审议情况 会议应出席监事 3 人，出席和授权出席监事 3 人。 1. 会议召开时间：2023 年 8 月 25 日 上午 11:00 2. 会议召开地点：上海辰光医疗科技股份有限公司 三楼会议室 3. 会议召开方式：现场会议 4. 发出监事会会议通知的时间和方式：会议通知于 2023 年 8 月 15 日以微信和电话形式送达各位监事。 5. 会议主持人：ZHAO HUAWEI（赵华炜）先生 6. 召开情况合法、合规、合章程性说明： 1.议案内容： 该议案具体内容详见公司在北京证券交易所指定信息 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2023-087 上海辰光医疗科技股份有限公司 第五届董事会第三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 1.议案内容： 议案内容：该议案具体内容详见公司在北京证券交易所指定信息 披露平台（www.bse.cn）上披露的《2023 年半年度报告》(公告编 号:2023-089) 及《2023 年半年度报告摘要》(公告编号:2023-090)。 2.议案表决结果：同意 9 票；反对 0 票；弃权 0 票。 3.回避表决情况： 本议案不涉及回避表决。 4.提交股东大会表决情况： 一、会议召开和出席情况 （一）会议召开情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 1.会议召开时间：2023 年 8 月 25 日 上午 9:00 2.会议召开地点：上海辰光医疗科技股份有限公司 三楼会议室 3.会议召开方式：现场会议 4. 发出董事会会议通知的时间和方式：会议通知于 2023 年 8 月 15 日以微信和电话形式送达各位董事 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2023-092 上海辰光医疗科技股份有限公司 关于子公司取得医疗器械经营许可证及第二类医疗器械经 营备案凭证的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 上海辰光医疗科技股份有限公司（以下简称"公司"）子公司上 海辰瞻医疗科技有限公司（以下简称"辰瞻医疗"）近期取得了上海 市青浦区市场监督管理局颁发的《医疗器械经营许可证》及《第二类 医疗器械经营备案凭证》。 一、 具体情况 法定代表人：王杰 企业负责人：林海洋 经营范围： 1. 上海市青浦区市场监督管理局颁发的《医疗器械经营许可证》，具 体情况如下： 公司名称：上海辰瞻医疗科技有限公司 统一社会信用代码：91310118MA1JLR9K5H 许可证编号：沪青药监械经营许 20230564 号 住所：上海市青浦区华青路 1269 号 150-168 室 【原《分类目录》分类编码区】：三类：6830 医用 X 射线设备； 【新《分类目录》分类编码区】：三类：06 医用成像器械。 许可期限：自 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2023-091 上海辰光医疗科技股份有限公司 募集资金存放与实际使用情况的专项报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、募集资金基本情况 （一）实际募集资金金额、资金到账情况 经中国证券监督管理委员会《关于同意上海辰光医疗科技股份 有限公司向不特定合格投资者公开发行股票注册的批复》(证监许 可[2022]2882 号)，同意公司向不特定合格投资者公开发行股票的 注册申请。公司于 2022 年 12 月 7 日成功在北京证券交易所上市。 公司首次发行股数 1,500.00 万股，发行价格为人民币 6 元/股，共 计募集资金人民币 9,000.00 万元，扣除承销和保荐费用 900.00 万 元后的募集资金为人民币 8,100.00 万元。已由海通证券股份有限 公司于 2022 年 11 月 30 日分别存入公司开立在中国建设银行股份 有 限 公 司 上 海 长 三 角 一 体 化 示 范 区 支 行 账 号 为 31050183360 ...

Strategic Partnerships and Market Expansion - In April 2023, the company signed a strategic cooperation agreement with Zhejiang Kangda Aotai Medical Technology Co., Ltd., which is expected to positively impact the company's operational performance and market expansion[5]. - The company has implemented a strategic focus on expanding its market presence through partnerships and technological advancements[5]. - The company expanded its business scope to include MRI equipment, completing the necessary business registration for the sale and leasing of medical devices[38]. - The domestic MRI market is projected to grow to ¥24.4 billion by 2030, with 3.0T systems expected to be a major growth driver[41]. Financial Performance - The company's operating revenue for the current period is ¥56,084,453.17, representing a 0.49% increase compared to ¥55,811,694.58 in the same period last year[27]. - The net profit attributable to shareholders of the listed company was -¥2,658,811.01, a 39.66% improvement from -¥4,406,417.94 in the same period last year[27]. - The gross profit margin improved to 39.17%, up from 37.84% in the previous year[27]. - The company's revenue for the reporting period was CNY 56,084,453.17, representing a year-on-year increase of 0.49%[55]. - The net profit improved by 36.21% to a loss of CNY 3,044,782.67, primarily due to government support funds received[49]. Research and Development - The company continues to focus on R&D in MRI systems and has maintained its direct sales model to downstream MRI equipment manufacturers and integrators[35]. - Research and development expenses amounted to ¥11,024,519.45, representing a 91.91% increase from the previous year, accounting for 19.66% of total revenue[38]. - Key R&D achievements include the completion of prototype testing for a 1.5T integrated RF coil and the initiation of prototype production for a 3.0T superconducting magnet[39]. - Research and development investment rose by CNY 527,980 during the reporting period[68]. Intellectual Property - As of June 30, 2023, the company holds a total of 74 valid patents, including 15 invention patents and 49 utility model patents[6]. - The company has 32 invention patents and 1 utility model patent currently under application review, indicating ongoing innovation efforts[6]. - The company holds 74 domestic and international patents and 5 software copyrights as of June 30, 2023[34]. Shareholder and Capital Structure - The total number of ordinary shares increased from 83,597,126 to 85,847,126 due to a public offering of 2,250,000 shares[88]. - The largest shareholder, Wang Jie, holds 27.22% of the company’s shares, totaling 23,365,988 shares[91]. - The company issued 2,250,000 shares at a price of 6 RMB per share, raising a total of 13,500,000 RMB, which will be used to supplement working capital[94]. - The total subscribed capital of the company is 400 million yuan, with a paid-in capital of 400 million yuan, representing a 100% contribution rate[153]. Risk Management - The company faces risks related to continuous technological innovation and potential talent shortages in the MRI field[69]. - The company has established measures to protect intellectual property and attract talent to strengthen its core competitiveness[69]. - The company faces risks related to foreign exchange fluctuations, which directly impact its export pricing competitiveness and operational performance[71]. - The company has reported no significant changes in major risks during the current period[72]. Governance and Management - The company has a total of 9 board members and 3 supervisory board members as of the report date[98]. - The company appointed Wang Jie as Chairman and General Manager, with a term from May 15, 2023, to May 14, 2026[98]. - The company has maintained a stable governance structure with a board of directors and several specialized committees[145]. Financial Position - Total assets at the end of the reporting period reached ¥439,857,376.05, a decrease of 0.33% compared to the previous year[37]. - Total liabilities decreased by 5.36% to ¥141,267,294.02 from the previous year[37]. - Net assets attributable to shareholders increased by 2.34% to ¥303,045,168.87[37]. - The company's total assets as of June 30, 2023, were ¥439,857,376.05, down from ¥441,329,792.83 at the end of 2022[113]. Cash Flow and Financing Activities - Cash flow from operating activities improved by 42.71%, reaching -¥13,154,968.85[37]. - The company raised ¥12,150,000.00 from new investments and ¥49,400,000.00 from borrowings, totaling ¥61,550,000.00 in cash inflows from financing activities[125]. - The net cash flow from financing activities was CNY 1,668,956.19, a turnaround from a net outflow of CNY -1,198,421.98 in the same period last year[127]. Compliance and Reporting - The financial statements were approved for release by the company's board on August 29, 2023[146]. - The company has not changed its accounting policies or estimates compared to the previous year's financial statements[143]. - The company has not reported any significant asset impairment losses or contingent liabilities during the reporting period[143].

证券代码：430300 证券简称：辰光医疗 公告编号：2023-086 上海辰光医疗科技股份有限公司 关于北京分公司完成工商登记并取得营业执照 的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 一、 基本情况 上海辰光医疗科技股份有限公司（以下简称"公司"）基于战略 发展需要，根据相关法律法规、规范性文件及《公司章程》的规定， 公司在北京设立分公司，并于近日取得由北京市通州区市场监督管理 局核发的营业执照。 二、 营业执照基本信息 目前，公司已经完成工商登记手续，并取得北京市通州区市场监 督管理局核发的营业执照。登记情况如下： 统一社会信用代码：91110112MACTYFR03C 许可项目：第三类医疗器械经营；第三类医疗器械租赁。（依法须经 批准的项目，经相关部门批准后方可开展经营活动，具体经营项目以 相关部门批准文件或许可证件为准）（不得从事国家和本市产业政策 禁止和限制类项目的经营活动。） 三、 备查文件目录 类型：股份有限公司分公司（上市、自然人投资或控股） 住所：北京市通州区榆西一街 1 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2023-076 上海辰光医疗科技股份有限公司 关于接待机构投资者调研情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 上海辰光医疗科技股份有限公司（以下简称"公司"）于 2023 年 5 月 29 日接待了 26 家机构的调研，现将主要情况公告如下： 一、 调研情况 调研时间：2023 年 5 月 29 日 调研地点：上海市青浦区华青路 1269 号 三楼会议室 调研形式：现场调研 调研机构：富国基金、德邦基金、国寿安保、华夏基金、申万菱 信、南方基金、太平资产、国泰君安证券、申万宏源证券、东方证券、 东海证券、东莞证券、万和证券、华鑫证券、首创证券、红塔证券、 鑫疆投资、宏道投资、洪顺投资、腾硕基金、观合资产、指南基金、 中证信用、开源证券、湘财证券、乾惕投资。 上市公司接待人员： 公司董事、副总经理、研发总监：王为先生 公司董事会秘书：于玲女士 公司监事、技术顾问：Zhao HuaWei（赵华炜）先生 证券事务代表：方国苏先生 二、 ...

Financial Performance - Operating revenue for Q1 2023 was CNY 19,549,204.28, representing a year-on-year increase of 10.41%[10] - The total revenue for the company reached 46,732,868, with a year-on-year growth of 54.38%[10] - The company reported a net profit of 1,369,000, reflecting a growth rate of 1.59%[10] - The net profit for Q1 2023 was a loss of ¥5,017,164.38, compared to a loss of ¥1,502,363.92 in Q1 2022, reflecting a deterioration in performance[37] - The total comprehensive income for Q1 2023 was -4,524,008.02, compared to -794,661.06 in Q1 2022, indicating a worsening financial position[41] Assets and Liabilities - Total assets as of March 31, 2023, were CNY 436,951,728.18, a decrease of 0.99% compared to the end of 2022[10] - The company's total assets decreased to ¥433,235,143.97 in Q1 2023 from ¥445,373,260.47 in Q1 2022, a decline of approximately 2.9%[35] - Total liabilities decreased to ¥140,486,801.34 in Q1 2023 from ¥160,250,909.82 in Q1 2022, a reduction of about 12.3%[35] - Total liabilities decreased to ¥137,460,304.70 from ¥149,269,302.09, a reduction of about 7.9%[31] - Current liabilities decreased to ¥107,862,339.15 from ¥120,966,395.31, reflecting a decrease of approximately 10.8%[30] Equity and Share Capital - The company issued additional shares, increasing total share capital to 85,847,126 shares by the end of the reporting period[17] - Shareholders' equity increased to ¥299,491,423.48 from ¥292,060,490.74, an increase of about 2.4%[31] - The company's equity increased to ¥292,748,342.63 in Q1 2023 from ¥285,122,350.65 in Q1 2022, showing a growth of approximately 2.3%[35] Cash Flow - Cash flow from operating activities improved by 43.97%, with a net cash outflow of CNY 10,410,561.45 compared to CNY 18,579,497.50 in the previous year[10] - Cash flow from operating activities for Q1 2023 was -10,410,561.45, an improvement from -18,579,497.50 in Q1 2022[42] - Total cash inflow from financing activities in Q1 2023 was 29,400,000.00, compared to 18,450,000.00 in Q1 2022, indicating a 59.5% increase[44] Research and Development - Research and development expenses increased by 94.44% in Q1 2023, primarily due to projects not reaching capitalization milestones[12] - Research and development expenses for Q1 2023 were ¥2,564,982.42, compared to ¥1,319,186.47 in Q1 2022, indicating an increase of about 94.3%[36] - Research and development expenses rose to 2,201,483.58 in Q1 2023, up from 1,319,046.47 in Q1 2022, marking a 66.67% increase[40] Inventory and Receivables - Accounts receivable decreased by 30.75% compared to the beginning of the period, reflecting improved collection efforts[11] - Inventory increased by 32.57% as the company ramped up production and stockpiled raw materials[11] - Accounts receivable decreased to ¥72,647,648.57 from ¥104,902,192.43, representing a significant drop of about 30.7%[29] - Inventory increased to ¥92,184,986.76 from ¥69,539,290.67, marking an increase of approximately 32.5%[29] Corporate Activities - The company has no ongoing litigation or arbitration matters reported during the period[22] - The company has fulfilled its commitments regarding previously disclosed matters in a timely manner[22] - The company has not engaged in any significant mergers or acquisitions during the reporting period[22] - The company has plans for market expansion and new product development in the upcoming quarters[23] - The company plans to focus on market expansion and new product development in the upcoming quarters[32]

证券代码：430300 证券简称：辰光医疗 公告编号：2023-042 上海辰光医疗科技股份有限公司 年度报告说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 一、 说明会类型 上海辰光医疗科技股份有限公司（以下简称"公司"）于 2023 年 4 月 12 日在北京证券交易所信息披露平台（www.bse.cn）披露 了《2022 年年度报告》（公告编号：2023-030）及《2022 年年度报 告摘要》（公告编号：2023-031），为方便广大投资者更深入了解 公司 2022 年年度经营业绩的具体情况，加强与投资者的互动交流， 公司拟召开 2022 年年度报告业绩说明会。 二、 说明会召开的时间、地点 （一）会议召开时间：2023 年 4 月 21 日（星期五）15:00-17:00。 （二）会议召开地点 本次业绩说明会将采用网络远程的方式举行，投资者可登录全 景网"投资者关系互动平台"（https://ir.p5w.net）参与本次年 报业绩说明会。 董事会秘书：于玲女士 财务负责人：郑 ...